Do analysts recommend GRDX or RVPH?

Reviva Pharmaceuticals has a consensus target price of $66.67, indicating a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is GRDX or RVPH more profitable?

Entero Therapeutics' return on equity of -49.81% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Reviva Pharmaceuticals N/A -391.58% -119.08%

Is RVPH or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Reviva Pharmaceuticals N/A -391.58% -119.08% Ayala Pharmaceuticals N/A N/A N/A

Which has preferable earnings & valuation, RVPH or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Reviva Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Reviva Pharmaceuticals N/A N/A -$19.86M -$4.06 N/A Zhengye Biotechnology $16.64M 2.20 -$9.98M N/A N/A

Is RVPH or ZYBT more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Reviva Pharmaceuticals N/A -391.58% -119.08% Zhengye Biotechnology N/A N/A N/A

Do analysts recommend BGM or RVPH?

Reviva Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, BGM or RVPH?

BGM Group has higher revenue and earnings than Reviva Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $25.10M 1.32 -$1.44M N/A N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$4.06 N/A

Is BGM or RVPH more profitable?

BGM Group's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Reviva Pharmaceuticals N/A -391.58% -119.08%

Do analysts recommend GRML or RVPH?

Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Greenland Mines Ltd. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, GRML or RVPH?

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$4.06 N/A

Is GRML or RVPH more profitable?

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Greenland Mines Ltd. Common Stock N/A -109.40% -98.80% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media refer more to GRML or RVPH?

In the previous week, Greenland Mines Ltd. Common Stock and Greenland Mines Ltd. Common Stock both had 3 articles in the media. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat Greenland Mines Ltd. Common Stock's score of 0.13 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenland Mines Ltd. Common Stock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Reviva Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Reviva Pharmaceuticals (RVPH) Competitors

$0.67 -0.03 (-3.60%)

As of 06/24/2026 03:48 PM Eastern

Compare

RVPH vs. GRDX, ADXS, ZYBT, BGM, and GRML

Should you buy Reviva Pharmaceuticals stock or one of its competitors? MarketBeat compares Reviva Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Reviva Pharmaceuticals include Entero Therapeutics (GRDX), Ayala Pharmaceuticals (ADXS), Zhengye Biotechnology (ZYBT), BGM Group (BGM), and Greenland Mines Ltd. Common Stock (GRML). These companies are all part of the "pharmaceutical products" industry.

How does Reviva Pharmaceuticals compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Entero Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Reviva Pharmaceuticals has a consensus target price of $66.67, indicating a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Entero Therapeutics' return on equity of -49.81% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Reviva Pharmaceuticals had 3 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 0 mentions for Entero Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat Entero Therapeutics' score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Reviva Pharmaceuticals	Neutral

Entero Therapeutics has higher revenue and earnings than Reviva Pharmaceuticals. Entero Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	734.83	-$6.39M	-$1.88	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

Summary

Reviva Pharmaceuticals beats Entero Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Ayala Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Reviva Pharmaceuticals has higher earnings, but lower revenue than Ayala Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Ayala Pharmaceuticals' return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Ayala Pharmaceuticals	N/A	N/A	N/A

In the previous week, Reviva Pharmaceuticals had 3 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 0 mentions for Ayala Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat Ayala Pharmaceuticals' score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
Ayala Pharmaceuticals	Neutral

Reviva Pharmaceuticals currently has a consensus price target of $66.67, suggesting a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Reviva Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Summary

Reviva Pharmaceuticals beats Ayala Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Zhengye Biotechnology?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Reviva Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.4, suggesting that its share price is 340% less volatile than the broader market.

Reviva Pharmaceuticals presently has a consensus target price of $66.67, suggesting a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Reviva Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zhengye Biotechnology has higher revenue and earnings than Reviva Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
Zhengye Biotechnology	$16.64M	2.20	-$9.98M	N/A	N/A

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Reviva Pharmaceuticals had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 0 mentions for Zhengye Biotechnology. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat Zhengye Biotechnology's score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
Zhengye Biotechnology	Neutral

Zhengye Biotechnology's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Zhengye Biotechnology	N/A	N/A	N/A

Summary

Reviva Pharmaceuticals beats Zhengye Biotechnology on 8 of the 12 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to BGM Group?

BGM Group (NASDAQ:BGM) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Reviva Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Reviva Pharmaceuticals had 3 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 0 mentions for BGM Group. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat BGM Group's score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
BGM Group	Neutral
Reviva Pharmaceuticals	Neutral

BGM Group's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

BGM Group has higher revenue and earnings than Reviva Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.32	-$1.44M	N/A	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BGM Group has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Summary

BGM Group and Reviva Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Greenland Mines Ltd. Common Stock and Greenland Mines Ltd. Common Stock both had 3 articles in the media. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat Greenland Mines Ltd. Common Stock's score of 0.13 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenland Mines Ltd. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Reviva Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Greenland Mines Ltd. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A

Greenland Mines Ltd. Common Stock has a beta of 6.94, suggesting that its stock price is 594% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Summary

Greenland Mines Ltd. Common Stock and Reviva Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVPH vs. The Competition

Export

Metric	Reviva Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.78M	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	-0.17	18.65	25.14	23.95
Price / Sales	N/A	341.96	531.12	107.90
Price / Cash	N/A	56.64	45.29	53.76
Price / Book	0.45	4.14	10.77	6.41
Net Income	-$19.86M	$64.45M	$3.56B	$337.14M
7 Day Performance	9.84%	1.22%	1.00%	-1.06%
1 Month Performance	62.23%	0.95%	0.81%	0.49%
1 Year Performance	-95.61%	25.22%	30.27%	28.43%

Reviva Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVPH Reviva Pharmaceuticals	3.0989 of 5 stars	$0.67 -3.6%	$66.67 +9,850.2%	-95.8%	$8.78M	N/A	N/A	5
GRDX Entero Therapeutics	0.2049 of 5 stars	$4.86 -10.0%	N/A	N/A	$35.93M	$40K	N/A	9
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
ZYBT Zhengye Biotechnology	N/A	$0.72 -4.3%	N/A	-89.8%	$35.54M	$16.64M	N/A	278	Gap Up
BGM BGM Group	0.4441 of 5 stars	$0.33 -9.1%	N/A	-97.4%	$35.49M	$25.10M	N/A	298	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVPH) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. GRDX, ADXS, ZYBT, BGM, and GRML

How does Reviva Pharmaceuticals compare to Entero Therapeutics?

Summary

How does Reviva Pharmaceuticals compare to Ayala Pharmaceuticals?

Summary

How does Reviva Pharmaceuticals compare to Zhengye Biotechnology?

Summary

How does Reviva Pharmaceuticals compare to BGM Group?

Summary

How does Reviva Pharmaceuticals compare to Greenland Mines Ltd. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. GRDX, ADXS, ZYBT, BGM, and GRML

How does Reviva Pharmaceuticals compare to Entero Therapeutics?

Which has more volatility and risk, GRDX or RVPH?

Do analysts recommend GRDX or RVPH?

Is GRDX or RVPH more profitable?

Do insiders & institutionals have more ownership in GRDX or RVPH?

Does the media refer more to GRDX or RVPH?

Which has higher earnings and valuation, GRDX or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Ayala Pharmaceuticals?

Which has preferable earnings and valuation, RVPH or ADXS?

Is RVPH or ADXS more profitable?

Does the media favor RVPH or ADXS?

Do analysts prefer RVPH or ADXS?

Do institutionals and insiders hold more shares of RVPH or ADXS?

Which has more risk and volatility, RVPH or ADXS?

Summary

How does Reviva Pharmaceuticals compare to Zhengye Biotechnology?

Which has more risk and volatility, RVPH or ZYBT?

Do analysts recommend RVPH or ZYBT?

Which has preferable earnings & valuation, RVPH or ZYBT?

Do institutionals & insiders hold more shares of RVPH or ZYBT?

Does the media favor RVPH or ZYBT?

Is RVPH or ZYBT more profitable?

Summary

How does Reviva Pharmaceuticals compare to BGM Group?

Do analysts recommend BGM or RVPH?

Does the media favor BGM or RVPH?

Is BGM or RVPH more profitable?

Which has better valuation and earnings, BGM or RVPH?

Do insiders and institutionals hold more shares of BGM or RVPH?

Which has more volatility & risk, BGM or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Greenland Mines Ltd. Common Stock?

Do insiders & institutionals hold more shares of GRML or RVPH?

Does the media refer more to GRML or RVPH?

Do analysts recommend GRML or RVPH?

Is GRML or RVPH more profitable?

Which has higher earnings & valuation, GRML or RVPH?

Which has more risk and volatility, GRML or RVPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools